Table 2.

Relationship of CEUS enhancement parameters with PSA, Gleason score and clinical stages

		No. of patients	Inner gland				Outer gland
			IMAX (%)	RT (s)	TTP (s)	mTT (s)	IMAX (%)	RT (s)	TTP (s)	mTT (s)
PSA	≤ 10	26	256.4 ± 51.4	12.3 ± 5.0	18.3 ± 10.2	37.0 ± 11.6	120.7 ± 56.6	14.0 ± 4.5	18.8 ± 7.6	33.0 ± 7.1
	10-20	16	218.1 ± 45.2	11.9 ± 4.0	14.9 ± 7.5	36.6 ± 14.2	118.1 ± 41.0	11.9 ± 2.4	15.5 ± 4.8	31.8 ± 7.8
	≥ 20	42	242.1 ± 84.2	12.2 ± 4.5	16.8 ± 8.9	35.0 ± 20.3	126.2 ± 46.1	13.0 ± 3.7	17.3 ± 6.2	31.4 ± 7.7
	P		0.224	0.950	0.482	0.883	0.821	0.217	0.287	0.323
Gleason score	< 7	27	224 ± 39.9	12.3 ± 4.4	17.6 ± 8.7	34.9 ± 11.7	122.6 ± 55.9	14.2 ± 3.4	18.9 ± 6.7	34.1 ± 8.9
	7	29	269.3 ± 93.3	11.9 ± 4.3	16.2 ± 9.4	40.0 ± 224.1	122.1 ± 52.2	12.3 ± 3.7	16.8 ± 6.0	29.9 ± 5.8
	> 7	28	230.6 ± 55.5	12.4 ± 4.9	16.9 ± 9.0	322.7 ± 10.1	124.1 ± 36.5	12.7 ± 4.0	16.6 ± 6.7	30.3 ± 7.7
	P		0.029	0.918	0.855	0.246	0.988	0.156	0.361	0.080
Clinical stages	T1c-T2a	37	233.1 ± 46.1	12.5 ± 4.6	18.2 ± 9.4	39.3 ± 22.3	123.6 ± 55.2	14.1 ± 3.3	19.1 ± 6.5	33.2 ± 7.8
	T2b-2c	25	260.1 ± 103.3	11.3 ± 5.0	15.1 ± 9.1	32.7 ± 12.6	103.6 ± 44.1	12.1 ± 4.0	16.4 ± 6.2	30.0 ± 8.6
	≥ T3a	22	236.3 ± 52.6	12.6 ± 3.9	16.9 ± 8.1	34.0 ± 6.1	143.7 ± 29.6	12.4 ± 4.1	15.8 ± 6.4	29.8 ± 5.7
	P		0.298	0506	0.422	0.265	0.016	0.077	0.107	0.145